fashion -WSS

fashion

author：focus 2025-09-29 01:39:05 - browse：73

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： FTC falls short on scrutinizing hospital mergers, study says

WSS

Cancer researcher Catriona Jamieson is sending tumors into space

American woman, child freed after being kidnapped in Haiti last month

Wegovy trial has doctors encouraged over new possibilities

Naloxone nonprofit donates 200,000 doses after FDA approval

Diversity in clinical trials starts with building trust, experts say

Medical bills so high, Medicare adding extra digits to claim forms

focus

fashion

A looming test for neoantigen cancer vaccines

hotspot

In Memoriam: Notable people who died in 2023

After traumatic brain injury, life support decisions can use more time

What does generative AI mean for health care? We asked experts

H5N1 bird flu found in pasteurized milk: what we know

Walensky prepares to leave CDC — and Congress — behind

MassMutual is introducing free genetic testing for members

United colonoscopy coverage change 'may cost lives,' doctors say

Exact Sciences stock tumbles despite strong cancer detection sales

Medicare details structure of new drug price negotiation program

FTC falls short on scrutinizing hospital mergers, study says

entertainment

Cancer researcher Catriona Jamieson is sending tumors into space

H5N1 bird flu found in pasteurized milk: what we know

More tobacco lobbyists active in statehouses

Exact Sciences stock tumbles despite strong cancer detection sales

Cue Health's Covid

Close Medicare's dangerous gaps in addiction treatment coverage

knowledge

focus

explore

focus